Company / Current Liabilities
Cullinan Therapeutics, Inc. Current Liabilities History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$30.6M
FY2024
5-year range
$11.7M / $30.6M
FY2020-FY2024
Trend
+8.9%
vs FY2023
Sector context
#176 of 213
Health Care
What the data says
Cullinan Therapeutics, Inc.'s current liabilities of $31M is lower than 83% of companies in the Health Care sector (FY2024). Current Liabilities has increased for 3 consecutive years, from $12M in FY2021 to $31M in FY2024.
Based on SEC 10-K filings.
$31M in FY2024 with a 3-year CAGR of +37.7%.
Increased from $22M to $31M over the past 2 years.
Health Care sector context is included.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- +37.7%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 17% in Health CareTop 17% of 213This company $30.6M Sector average $1.6B
▼
-98.1% below sector average
Key checks
Key Insights
- Cullinan Therapeutics, Inc.'s current liabilities has grown for 3 consecutive years.
- 3-year CAGR of +37.7%, indicating consistent growth.
- In FY2024, current liabilities increased 8.9% year-over-year.
- Ranks #176 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 7.33 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $30.6M | +8.9% |
| FY2023 | $28.1M | +25.1% |
| FY2022 | $22.5M | +91.5% |
| FY2021 | $11.7M | -18.0% |
| FY2020 | $14.3M | - |
As of FY2024 · SEC 10-K · Updated Jul 2, 2026